Adverse events
| . | All (%) . | Grade ≥3 . |
|---|---|---|
| Hematologic adverse events | ||
| Neutrophil count decreased | 29 (60%) | 16 (33%) |
| Anemia | 29 (60%) | 5 (10%) |
| White blood cell decreased | 26 (54%) | 9 (19%) |
| Platelet count decreased | 23 (48%) | 7 (15%) |
| Lymphocyte count decreased | 4 (8%) | 3 (6%) |
| Nonhematologic adverse events | ||
| Fatigue | 36 (75%) | 1 (2%) |
| Infections (all) | 36 (75%) | 16 (33%) |
| Upper respiratory infection | 29 (60%) | 2 (4%) |
| Lung infection | 16 (33%) | 13 (27%) |
| Hyperglycemia | 27 (56%) | 2 (4%) |
| Diarrhea | 27 (56%) | 1 (2%) |
| Pain, musculoskeletal | 26 (54%) | 2 (4%) |
| Dyspnea | 21 (44%) | 1 (2%) |
| Constipation | 19 (40%) | 1 (2%) |
| Hypophosphatemia | 18 (38%) | 9 (19%) |
| Peripheral sensory neuropathy | 18 (38%) | 0 |
| Insomnia | 17 (35%) | 0 |
| Cough | 14 (29%) | 0 |
| Edema limbs | 14 (29%) | 0 |
| Hyponatremia | 13 (27%) | 3 (6%) |
| Hypocalcemia | 12 (25%) | 0 |
| Hypomagnesemia | 12 (25%) | 0 |
| Nausea | 12 (25%) | 0 |
| Hypoalbuminemia | 11 (23%) | 0 |
| Hypertension | 10 (21%) | 1 (2%) |
| Maculopapular rash | 9 (19%) | 3 (6%) |
| Thromboembolic event | 4 (8%) | 4 (8%) |
| . | All (%) . | Grade ≥3 . |
|---|---|---|
| Hematologic adverse events | ||
| Neutrophil count decreased | 29 (60%) | 16 (33%) |
| Anemia | 29 (60%) | 5 (10%) |
| White blood cell decreased | 26 (54%) | 9 (19%) |
| Platelet count decreased | 23 (48%) | 7 (15%) |
| Lymphocyte count decreased | 4 (8%) | 3 (6%) |
| Nonhematologic adverse events | ||
| Fatigue | 36 (75%) | 1 (2%) |
| Infections (all) | 36 (75%) | 16 (33%) |
| Upper respiratory infection | 29 (60%) | 2 (4%) |
| Lung infection | 16 (33%) | 13 (27%) |
| Hyperglycemia | 27 (56%) | 2 (4%) |
| Diarrhea | 27 (56%) | 1 (2%) |
| Pain, musculoskeletal | 26 (54%) | 2 (4%) |
| Dyspnea | 21 (44%) | 1 (2%) |
| Constipation | 19 (40%) | 1 (2%) |
| Hypophosphatemia | 18 (38%) | 9 (19%) |
| Peripheral sensory neuropathy | 18 (38%) | 0 |
| Insomnia | 17 (35%) | 0 |
| Cough | 14 (29%) | 0 |
| Edema limbs | 14 (29%) | 0 |
| Hyponatremia | 13 (27%) | 3 (6%) |
| Hypocalcemia | 12 (25%) | 0 |
| Hypomagnesemia | 12 (25%) | 0 |
| Nausea | 12 (25%) | 0 |
| Hypoalbuminemia | 11 (23%) | 0 |
| Hypertension | 10 (21%) | 1 (2%) |
| Maculopapular rash | 9 (19%) | 3 (6%) |
| Thromboembolic event | 4 (8%) | 4 (8%) |
All grade adverse events ≥20%; and grade ≥3 adverse events ≥5% are shown.